The reported decrease in EPS and a slight drop in revenue are typically seen as negative indicators for a company's financial performance, which can lead to a bearish outlook among investors in the short term. The direct mention of Arrowhead Pharmaceuticals with specific financial figures makes the news highly relevant and important for investors, although the slight nature of the revenue decrease tempers the impact slightly.